Types of DTP vaccine
Vaccinations And Immunizations / / April 26, 2016
tetanus adsorbed liquid - DTP
Manufacturer: FSUE "NPO" Microgen "MH RF, Russia.
Product form. Produce DTP in vials of 1.0 ml (2 doses of vaccination).The pack contains 10 ampoules.
vaccination scheme: prevention of diphtheria, pertussis, tetanus, according to the national immunization schedule in children three times with an interval of 1.5 months (3 months - 4.5 months - 6 months).
Instructions for use
vaccine pertussis-diphtheria-tetanus toxoids adsorbed fluid (DTP) vaccine suspension for injection.
composition. DTP vaccine consists of a suspension of killed pertussis bacteria and purified toxoids, tetanus and diphtheria, adsorbed on aluminum hydroxide.
Preservative - thimerosal at a concentration of 0.01%.Contains in 1 ml 20 billion. Pertussis bacterial cells, 30 flocculating units (Lf) diphtheria antitoksinsvyazyvayuschih units (EU), tetanus toxoid.The single primary dose (0.5 ml) contains not less than 30 international units IU (MIE) of diphtheria toxoid, not less than 60 of teta
Properties. DTP vaccine in the human body causes the formation of specific immunity against pertussis, diphtheria and tetanus.
Appointment. drug is intended for routine prophylaxis of whooping cough, diphtheria and tetanus in children between the ages of 3 months for the special scheme.
Application. Vaccinations DTP vaccine is carried out between the ages of 3 months.Before reaching the age of 3 years 11 months.29 days.(Vaccinations for children who recover from whooping cough, hold Td toxoid).DTP vaccine is administered intramuscularly in the upper outer quadrant of the buttocks at a dose of 0.5 mL (single dose vaccination).vaccination course consists of 3 vaccinations with an interval of 1.5 months (3 months, 4.5 months, 6 months.) DTP vaccine can be administered simultaneously with poliomyelitis vaccine and other drugs in the national calendar of vaccination.Revaccination is carried out once at the age 18mes.(In violation of the terms of vaccinations - after 12-13 months after the last dose of DTP vaccine).
Note: If a child until 3 years 11mesyatsev 29dney.has not received DTP vaccine booster, then it is carried out Td toxoid (for ages 4 years - 5 years 11mesyatsev 29dney) or ADS - M toxoid (6 years and older)
Contraindications. progressive disease of the nervous system.Afebrile seizures in history.Development in the previous administration of DTP vaccine strong general reactions (fever in the first two days to 40 or higher) or complications.
1. Children with contraindications to the use of DTP vaccine can be vaccinated DT - toxoid.
2. If the child is vaccinated twice, the vaccination rate against diphtheria and tetanus is ended if the child received one vaccination, vaccination can be continued Td toxoid, which is administered once not earlier than 3 months.In both cases, the first revaccination spend Td toxoid in 9-12 months.After the last vaccination.If complications developed after the third vaccination DPT vaccine, the first revaccination spend Td toxoid 12-18 months.Subsequent revaccination is carried out at 7, 14, and every subsequent 10 years Td toxoid.
Storage. Store in a dry, dark place at a temperature (6 ± 2) ° C.Protect from freezing!
shelf life. 1 year 6 months.
Infanrix ™ / Infanrix ™ (diphtheria, pertussis, tetanus)
Infanrix ™ vaccine for the prevention of diphtheria, tetanus, pertussis atselyulyarnaya purified inactivated liquid (INFANRIX ™ combined diphteria, tetanus, acellular pertussis vaccine) GlaxoSmithKlineJ07A X (Belgium)
Structure and Composition: suspension for injection, 0.5 mL syringe, 1 dose, number 1
One dose (0.5 ml) contains at least 30 IU International (MIE) diphtheriatoxoid, not less than 40 of tetanus toxoid and MIE 25 ug detoxified pertussis toxin and filamentous haemagglutinin 25 micrograms and 8 micrograms pertactin.Diphtheria and tetanus toxoids obtained from cultures of Corynebacterium diphteriae and Clostridium tetani, inactivated and purified.Components acellular pertussis vaccine is prepared by growing Phase I Bordetella pertussis culture, from which is extracted and purified PT, FHA and pertactin.
Indications: active primary immunization against diphtheria, tetanus and pertussis in children from 3 months of age.
Application: primary vaccination regimen consists of three doses in the first year of life and can start from 3 months of age followed by a booster dose in the 2 nd and 6 th year of life.
vaccine Infanrix is for deep / m administration.The vaccine Infanrix should be administered with caution to persons with thrombocytopenia or impaired blood clotting, as with the / m introduction of local bleeding can occur in such individuals.The injection site should be pressed firmly (without rubbing) for at least 2 minutes.
Contraindications: vaccine Infanrix not appoint persons with a known hypersensitivity to any component of the vaccine or those who showed signs of hypersensitivity after previous administration of a vaccine for the prevention of diphtheria, tetanus and pertussis.
Introduction Infanrix is contraindicated in children, if the child has previously revealed encephalopathy of unknown origin within 7 days after the previous administration of a vaccine containing pertussis components.In this case, the course of vaccination the vaccine should continue with diphtheria and tetanus components.
Side effects: pain, redness, swelling, fever, unusual crying or screaming, vomiting, diarrhea, loss of appetite.
Interaction with other drugs: Infanrix vaccine can be administered simultaneously with other vaccines intended for immunizing children.The vaccine may be used in the same syringe with vaccines to prevent diseases caused by Haemophilus influenzae (type B).vaccine administration sites must necessarily be different.In patients receiving immunosuppressive therapy, and patients with immunodeficiency, an adequate immune response may not develop.
Storage: in a dry, dark place at a temperature of 2-8 ° C, do not freeze.The vaccine should be administered immediately after opening the vial (no more than 8 hours after opening the bottle).
Infanrix ™ IPV
Infanrix IPV (INFANRIX ™ IPV)
combination vaccine for diphtheria, tetanus, pertussis (acellular component) and poliomyelitis
Manufacture: GlaxoSmithKline J07C A02 (Belgium).
Structure and Composition: suspension for injection 0.5 ml syringe disp, 1 dose, number 1
vaccine dose of 0.5 ml contains not less than 30 IU of diphtheria toxoid, not less than 40 IU of tetanus toxoid, 25 mcg.pertussis toxoid, filamentous haemagglutinin 25 micrograms and 8 micrograms pertactin;40 D-antigen units of type 1, 8 D-antigen units of type 2 and 32 D-antigen units of type 3 virus inactivated polio.
Pharmacological properties: Infanrix IPV - the combination vaccine for diphtheria, tetanus, pertussis / acellular component / DTPa and polio (IPV).
Indications: prevention of diphtheria, tetanus, pertussis and polio in children aged 2 months.The vaccine Infanrix IPV is also indicated as a booster (a booster) dose for children who have previously been immunized with antigens of diphtheria, tetanus, pertussis and polio.
Application: primary vaccination regimen consists of 3 doses in the first year of life and can start at the age of 3 months.Between administration of subsequent doses should follow the interval of at least 1.5 months.Typically, the vaccine administered child aged 3;4yu5 and 6 months with a booster at 18 months.After completion of the primary vaccination regime should withstand interval of at least 6 months for the booster dose.Clinical data regarding the use of this vaccine as a booster dose were obtained for children up to 13 years.
vaccine Infanrix IPV is designed for deep / m administration.For infants the predominant site of injection is the anterolateral portion of the thigh;in older children, the vaccine should be administered in the deltoid muscle.Each subsequent dose is desirably administered at alternative sites.
Contraindications: vaccine Infanrix IPV should not be administered to persons with hypersensitivity to any component of the vaccine, or to persons with signs of hypersensitivity after previous administration of vaccines for the prevention of diphtheria, tetanus, pertussis and inactivated vaccines for polio prevention.
introduction of the vaccine Infanrix IPV is contraindicated if the child has marked encephalopathy of unknown origin within 7 days after previous vaccination vaccine containing pertussis components.
Cautions: vaccine Infanrix IPV should not be administered to persons with a known hypersensitivity to any component of the vaccine or those who showed signs of hypersensitivity after previous administration of vaccines for the prevention of diphtheria, tetanus, pertussis and inactivated vaccines for polio prevention.IPV Infanrix is contraindicated if the child has been featured encephalopathy of unknown origin within 7 days after previous vaccination vaccine containing pertussis components.Under no circumstances will the vaccine Infanrix IPV should not be administered intravenously.
Storage: Infanrix IPV vaccine should be stored at 2-8 ° C in a dark place.Should not be frozen;do not use if Infanrix IPV vaccine has been frozen.
Infanrix ™ HEXA / HEXA Infanrix ™
Diphtheria, pertussis, tetanus, hepatitis B, polio, Haemophilus influenzae type b.
Infanrix ™ HEXA combination vaccine for diphtheria, tetanus, pertussis (acellular component), hepatitis B, poliomyelitis and disease, the causative agent of which is Haemophilus influenzae type b (INFANRIX ™ HEXA combined diphtheria, tetanus, acellular pertussis, hepatitis B, enhanced inactivatedpolio vaccine and Haemophilus influenzae type b vaccine (DTPa-HBV-IPV / Hib))
Manufacturer: GlaxoSmithKline J07C A09 (Belgium)
Structure and Composition: suspension for injection, disp syringe + liofil..long.d / in.. Into vials, number 1
contains diphtheria toxoid, tetanus toxoid, three purified pertussis antigens (pertussis toxoid (the PT), filamentous hemagglutinin (the FHA) and pertactin (PRN; outer membrane protein weight of 69 kDa), purified primary surface antigen (HBsAg), hepatitis virus b (HBV) and purified poliribozil-ribitol phosphate capsular polysaccharide (PRP) Haemophilus influenzae type b (Hib), covalently bound to tetanus toxoid adsorbed onto aluminum salts. The vaccine also comprises inactivated polio viruses three types (IPV) (type 1: strain Mahoney, type 2: strain MEF-1, type 3: Saukett strain)
preparation is a suspension (DTPa-HBV-IPV) for injection in a disposable syringe and a lyophilized powder (Hib) for injecting into the vial.which are mixed before use
Pharmacological properties:. Tetanus and diphtheria toxoids are obtained by treating with formaldehyde treated toxin Corynebacterium diphtheriae and Clostridium tetani.The components of acellular pertussis vaccines are obtained by extraction and purification from cultures of a Bordetella pertussis phase I, which are accompanied by irreversible detoxification of pertussis toxin by treatment with glutaraldehyde and formaldehyde, formaldehyde and the treatment with FHA and PRN.Diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine components are adsorbed on aluminum salts.The components of DTPa-HBV-IPV prepared p-isotonic sodium chloride and D contain 2-phenoxyethanol.
HBV surface antigen is produced by culture of yeast cells (Saccharomyces cerevisiae), obtained by genetic engineering techniques that carry the gene coding for HBsAg.This thoroughly purified surface antigen physico-chemical methods.It spontaneously transformed into spherical particles of 20 nm in diameter that contain antigens nonglycosylated polypeptides and lipid matrix, consisting primarily of phospholipids with characteristic properties of the natural HBsAg.Poliovirus type 3 were cultured on VERO cell line, purified and inactivated with formaldehyde.Hib polysaccharide is prepared from Hib strain 20752 and connect to tetanus toxoid.After purification the conjugate is adsorbed onto aluminum salts and lyophilized in the presence of lactose as a stabilizer.Infanrix Hexa meets the WHO requirements for the production of biological substances, diphtheria, tetanus, pertussis and combined vaccines, vaccines for the prevention of hepatitis B obtained by recombinant DNA technology, inactivated poliomyelitis vaccines to prevent and Hib-conjugate vaccines.
Indications: vaccine Infanrix Hexa is indicated for primary immunization to prevent diphtheria, tetanus, pertussis, hepatitis B, polio and infections caused by Haemophilus influenzae type b in infants between the ages of 6 weeks and can be assigned to infants,who received the first dose of vaccine for the prevention of hepatitis B at birth.
Application: Infanrix Hexa vaccine injected deep into the / m in the vastus lateralis muscle in the anterolateral portion of the middle or upper thigh.
Contraindications: not prescribed to persons with a known hypersensitivity to any component of the vaccine or people who have observed hypersensitivity reactions after previous administration of vaccines for the prevention of diphtheria, tetanus, pertussis, hepatitis B, polio or Hib.
Introduction Infanrix Hexa is contraindicated if the child has previously observed an encephalopathy of unknown origin within 7 days after previous vaccination vaccine containing pertussis components.In this case, vaccination against whooping cough should stop and continue the course of vaccination with vaccines for diphtheria-tetanus, hepatitis B, inactivated polio vaccine and a vaccine for the prevention of Hib.
Side effects: in clinical trials, the most common reactions (frequency 10%) reported after primary vaccination were:
- local pain, redness, swelling;
- system: anorexia, fever, drowsiness, irritability.
In studies with the inclusion of 4083 persons (documented doses) of the reactions that are regarded as being caused or probably caused by vaccination, reported reactions at the injection site and irritability.
Very rarely reported allergic reactions, including anaphylactoid reactions after immunization with vaccines containing DTPa.
The vaccine with pertussis were reported very rare cases of collapse or shock-like state (hypotonic hyporesponsiveness episode) and convulsions within 2-3 days after vaccination.All vaccinated with similar reactions recovered without complications.
Storage: in a dark place at a temperature of 2-8 ° C.During transport should follow the recommended storage conditions.DTPa-HB-Ip-suspension and prepared for the introduction of the vaccine must not be frozen.
vaccine against diphtheria, tetanus, pertussis, polio and Haemophilus influenzae.
Manufacturer: «SanofiAventis Pasteur", France
Product form: 1shprits containing 1 dose of vaccine against diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type B
Instructions for use
vaccine isdiphtheria and tetanus adsorbed, acellular pertussis, inactivated poliomyelitis, infection caused by Haemophilus influenzae type b conjugate.
Dosage Form: lyophilisate for suspension for intramuscular injection of 1 dose, complete with suspension for intramuscular injection 0.5 ml.
composition and dosage: 1.Vaktsina diphtheria and tetanus adsorbed;acellular pertussis;inactivated poliomyelitis (suspension for intramuscular injection).One dose of vaccine (0.5 ml) contains:
- diphtheria toxoid ...?30 IU;
- tetanus toxoid ...?40 IU;life.